StemRIM (4599) FY2026 Earnings In-Depth Analysis: Achieving Primary Endpoints in EB Phase 2 and Ischemic Stroke Phase 2b Results; A Comprehensive Overview of Financials and Development Toward 2028

Executive Summary

For StemRIM Inc., a biopharmaceutical venture originating from Osaka University, the fiscal year ending July 2026 was a period marked by both significant progress in key milestones toward the commercialization of its proprietary "Regeneration-Inducing Medicine®" platform and a nuanced outlook for its pipeline development.

Financially, reflecting the typical revenue structure of a drug discovery venture, the company recorded zero business revenue due to the absence of upfront license payments or milestone income, resulting in an operating loss of 1.998 billion yen . However, with 5.377 billion yen in cash and deposits at the end of the fiscal year and a monthly cash burn rate of approximately 134 million yen, the company has sufficiently secured funding for R&D activities through 2028 .

In R&D, there was a critical breakthrough for its flagship pipeline, "Redasemtide (HMGB1 peptide)." In the additional Phase 2 clinical trial for Dystrophic Epidermolysis Bullosa (DEB), 3 out of 4 patients achieved the primary endpoint of "closure of refractory ulcers," providing solid evidence toward the target launch in the fiscal year ending March 2028. Conversely, in the global late-stage Phase 2b trial for acute ischemic stroke led by Shionogi & Co., the primary endpoint did not reach statistical significance compared to the placebo group. However, certain efficacy signals, such as an improvement trend in the severe patient subgroup, were confirmed. This report provides a multi-faceted analysis of the company's financial health, clinical development trends for each pipeline, and the progress of its next-generation platforms.

---

1. FY2026 Earnings Overview and Financial Health

StemRIM’s business model involves leading projects from basic research through non-clinical and early clinical trials, then licensing out (granting development, manufacturing, and marketing rights) to pharmaceutical companies to earn upfront payments, development milestones, and post-launch royalties.

Financial Highlights and Cash Runway Verification

As shown in the earnings summary slide above, the performance and financial status for the current period are as follows:

• Business Revenue : 0 million yen (Previous year: 0 million yen)
• R&D Expenses : 1,499 million yen (Up 111 million yen, +8.0% YoY)
• Total Operating Expenses : 1,998 million yen (Up 33 million yen, +1.7% YoY)
• Operating Loss : -1,998 million yen (Previous year: -1,971 million yen)
• Net Loss : -1,851 million yen (Previous year: -1,929 million yen)
• Cash and Deposits : 5,377 million yen (Down 1,617 million yen from previous year-end)

While business revenue was zero due to the lack of milestone-related income, R&D investment continued aggressively at 1.499 billion yen, in line with the plan. Annual cash expenditure, including SG&A, is approximately 1.6 billion yen (1.4 billion yen for R&D and 0.26 billion yen for SG&A), resulting in a monthly cash burn rate of approximately 134 million yen .

Given the year-end cash balance of 5.377 billion yen, it is confirmed that the company maintains a financial foundation capable of sustaining stable R&D activities through 2028 without additional external financing . This serves as a robust buffer to complete research while minimizing dilution risk as the pipeline advances through clinical stages.

---

2. Clinical Development Progress of Flagship Pipeline "Redasemtide"

StemRIM’s core compound, "Redasemtide (Development Code: TRIM2)," possesses an innovative mechanism that mobilizes ectodermal mesenchymal stem cells from bone marrow into the bloodstream, accumulating them in damaged tissues to promote functional regeneration. During this period, important clinical results were announced for two major indications.

(1) Dystrophic Epidermolysis Bullosa: Primary Endpoint Achieved in Additional Phase 2

DEB is a rare, intractable disease where congenital abnormalities in type VII collagen, which forms the skin's basement membrane, cause blisters and refractory ulcers across the body from minor stimuli. The additional Phase 2 clinical trial (single-arm, multi-center, open-label, non-controlled) conducted by StemRIM yielded highly favorable topline results.

• Primary Endpoint (Closure of refractory ulcers) : 3 out of 4 evaluated patients achieved ulcer closure , meeting the primary endpoint.
• Clinical Findings : Overall improvement in clinical symptoms, including total ulcer area, was confirmed in some cases.
• Safety and Tolerability : No new safety concerns attributable to Redasemtide were observed, and good tolerability was confirmed.

This indication was designated as an Orphan Drug by the Ministry of Health, Labour and Welfare in May 2023 and is eligible for the priority review system. According to disclosures from the licensee, Shionogi & Co., a launch by the fiscal year ending March 2028 is planned, making the development timeline for commercialization highly realistic.

(2) Acute Ischemic Stroke: Global Phase 2b Topline Results and Future Outlook

Topline results were disclosed for the global late-stage Phase 2 trial (conducted in Japan, Europe, North America, China, etc., with 679 patients total) for acute ischemic stroke patients led by Shionogi. The trial evaluated patients within 25 hours of onset, administering Redasemtide (1.5mg/kg) or placebo intravenously for 5 days, with the modified Rankin Scale (mRS) assessed 90 days after the start of administration.

• Primary Endpoint (Day 90 mRS) : No statistically significant difference was observed compared to the placebo group; the primary endpoint was not met.
• Efficacy Signal : Similar to the previous domestic Phase 2 trial, a trend toward mRS improvement was observed in the Redasemtide group.
• Subgroup Analysis : Exploratory analysis suggested an mRS improvement trend in the patient population with higher severity at onset .
• Safety : The incidence of adverse events was similar in both groups, reconfirming high safety.

While the failure to reach statistical significance in acute ischemic stroke is a short-term negative, obtaining an efficacy signal in the severe patient group provides critical data for narrowing the target patient population and restructuring development strategy.

(3) Ischemic Cardiomyopathy and Other Pipeline Progress

• Ischemic Cardiomyopathy : Patient enrollment was completed in April 2026 for the investigator-initiated Phase 1/2 trial targeting patients who underwent coronary artery bypass grafting (CABG). Follow-up is ongoing to evaluate cardiac function improvement after 52 weeks.
• Knee Osteoarthritis / Chronic Liver Disease : Investigator-initiated Phase 2 trials have been completed, and data organization is underway for the next stage of development and licensing.

---

3. Next-Generation Platforms and New Pipelines

StemRIM is accelerating the development of next-generation regeneration-inducing medicines and gene therapy technologies as mid-to-long-term growth drivers following Redasemtide.

Next-Generation Stem Cell Gene Therapy "SR-GT1"

A radical treatment where mesenchymal stem cells collected from the patient's own blister sites are transduced with the normal type VII collagen gene using a lentiviral vector and administered back into the blisters.

• Manufacturing Process Establishment : Successfully established a mass-culture process for stem cells, which was a development challenge.
• Development Schedule : As of 2026, robustness verification of cell manufacturing and non-clinical trials (safety evaluation via animal testing) are underway, with clinical trials scheduled to begin in 2028 .

New Peptide Series (TRIM3 / TRIM4 / TRIM5)

• TRIM3 / TRIM4 : Systemic administration-type novel peptides; licensing activities are currently underway with multiple domestic and international pharmaceutical companies.
• TRIM5 : Local administration-type novel peptide; data expansion in disease model animals is ongoing.

---

4. Intellectual Property Strategy and Global Expansion

To maximize the value of its development compounds and secure market exclusivity, the company is aggressively building a global patent network.

• IP Achievements (Aug 2025 – July 2026) : A total of 11 patents were registered across 5 indication areas: cartilage disease, cardiomyopathy/chronic heart failure, fatty liver/NASH, psoriasis, and epidermolysis bullosa.
• Registered Countries/Regions : Multi-faceted rights have been achieved in 7 countries and regions worldwide , including Japan, the US, Canada, Australia, Mexico, Russia, and South Korea.

This establishes strong barriers to entry for the global expansion of Redasemtide and SR-GT1.

---

5. Summary and Key Points to Watch

In the fiscal year ending July 2026, while facing the challenge of the unmet primary endpoint in the global Phase 2b trial for acute ischemic stroke, StemRIM achieved a major milestone directly linked to commercialization: meeting the primary endpoint in the additional Phase 2 trial for epidermolysis bullosa .

Key monitoring indicators for investors moving forward include:

1. Epidermolysis Bullosa (Redasemtide) : The approval application process by Shionogi & Co. and the timing of milestone achievements toward the March 2028 launch.
2. Acute Ischemic Stroke (Redasemtide) : Announcement of Shionogi’s development policy based on exploratory subgroup analysis (e.g., design of a Phase 3 trial targeting specific patients).
3. New Peptides (TRIM3/4) : Conclusion of new licensing agreements with domestic/international pharmaceutical companies and receipt of upfront payments.
4. Capital Management : Progress in the SR-GT1 clinical trial entry process while maintaining the cash runway through 2028 (5.38 billion yen in cash/deposits).

StemRIM’s progress in simultaneously advancing the launch of core indications and the commercialization of next-generation technologies, while maintaining financial stability, remains a key focus.